How many drugs treat Melanoma?

Drug Landscape tracks 2 marketed treatments for Melanoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/melanoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Melanoma — Treatment Landscape & Competitive Intelligence

Melanoma (Oncology) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology 2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Melanoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Keytruda	pembrolizumab	Merck & Co.	Monoclonal antibody; PD-1 inhibitor	PD-1 receptor		2014-01-01
Immuno-oncology (IO)	immuno-oncology-io	Pfizer	Not specified	Not specified

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 1 drug in Melanoma
Pfizer · 1 drug in Melanoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Melanoma:

Cite this brief

Drug Landscape (2026). Melanoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/melanoma. Accessed 2026-05-13.

Melanoma full disease profile — treatment pathway, diagnostics, guidelines
Oncology area landing
Browse all CI briefs
Build a custom feed